Inotuzumab Ozogamicin作为tisagenlecucel后复发的儿科BCP-ALL干细胞移植的桥梁:一个病例系列

IF 1.5 Q4 ONCOLOGY
Cancer reports Pub Date : 2025-03-14 DOI:10.1002/cnr2.70177
Margo Aertgeerts, Marleen Renard, Anne Uyttebroeck, Nancy Boeckx, Heidi Segers
{"title":"Inotuzumab Ozogamicin作为tisagenlecucel后复发的儿科BCP-ALL干细胞移植的桥梁:一个病例系列","authors":"Margo Aertgeerts,&nbsp;Marleen Renard,&nbsp;Anne Uyttebroeck,&nbsp;Nancy Boeckx,&nbsp;Heidi Segers","doi":"10.1002/cnr2.70177","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal. We report on four pediatric patients who relapsed after tisagenlecleucel and were treated with inotuzumab ozogamicin (InO).</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>Four patients with BCP-ALL received tisagenlecleucel after second relapse (3/4) or refractory disease at first relapse (1/4). Three patients relapsed with CD19<sup>NEG</sup>/CD22<sup>POS</sup> BCP-ALL, one with CD19<sup>POS</sup>/CD22<sup>POS</sup> BCP-ALL. Following relapse, they received treatment with InO. After the first InO cycle, all achieved complete remission (CR), three without measurable residual disease. After two or three InO cycles, they underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient developed an isolated extramedullary relapse (IEM) in both anterior eye chambers six and nine months after allo-HSCT and received palliative radiotherapy. This patient was in CR at the last follow-up 25 months later. The other patients were also in CR at the last follow-up (mean 31.3 months).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>InO can be used successfully and safely for the treatment of CD22<sup>POS</sup> BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70177","citationCount":"0","resultStr":"{\"title\":\"Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series\",\"authors\":\"Margo Aertgeerts,&nbsp;Marleen Renard,&nbsp;Anne Uyttebroeck,&nbsp;Nancy Boeckx,&nbsp;Heidi Segers\",\"doi\":\"10.1002/cnr2.70177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal. We report on four pediatric patients who relapsed after tisagenlecleucel and were treated with inotuzumab ozogamicin (InO).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case</h3>\\n \\n <p>Four patients with BCP-ALL received tisagenlecleucel after second relapse (3/4) or refractory disease at first relapse (1/4). Three patients relapsed with CD19<sup>NEG</sup>/CD22<sup>POS</sup> BCP-ALL, one with CD19<sup>POS</sup>/CD22<sup>POS</sup> BCP-ALL. Following relapse, they received treatment with InO. After the first InO cycle, all achieved complete remission (CR), three without measurable residual disease. After two or three InO cycles, they underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient developed an isolated extramedullary relapse (IEM) in both anterior eye chambers six and nine months after allo-HSCT and received palliative radiotherapy. This patient was in CR at the last follow-up 25 months later. The other patients were also in CR at the last follow-up (mean 31.3 months).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>InO can be used successfully and safely for the treatment of CD22<sup>POS</sup> BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9440,\"journal\":{\"name\":\"Cancer reports\",\"volume\":\"8 3\",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70177\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70177\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

cd19靶向嵌合抗原受体t细胞疗法tisagenlecleucel在治疗复发/难治性b细胞前体急性淋巴细胞白血病(BCP-ALL)的儿科患者中显示出有希望的结果。然而,约50%的患者在tisagenlecleure后复发。多次复发后,治疗选择有限,预后惨淡。我们报告了4例小儿患者在tisagenlecleucel后复发,并接受了inozumab ozogamicin (InO)治疗。4例BCP-ALL患者在第二次复发(3/4)或首次复发难治性疾病(1/4)后接受了tisagenleclear。3例复发为CD19NEG/CD22POS BCP-ALL, 1例复发为CD19POS/CD22POS BCP-ALL。复发后,接受InO治疗。在第一个InO周期后,所有患者均达到完全缓解(CR),其中3例无可测量的残留疾病。在两到三个InO周期后,他们接受了同种异体造血干细胞移植(alloo - hsct)。1例患者在同种异体造血干细胞移植6个月和9个月后,在两个前房发生孤立性髓外复发(IEM),并接受姑息性放疗。在25个月后的最后一次随访中,该患者处于CR状态。其他患者在最后一次随访时也处于CR(平均31.3个月)。结论InO可成功、安全的用于治疗CD22POS BCP-ALL复发,可作为重度预治儿童患者进行同种异体造血干细胞移植的桥梁。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series

Background

CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal. We report on four pediatric patients who relapsed after tisagenlecleucel and were treated with inotuzumab ozogamicin (InO).

Case

Four patients with BCP-ALL received tisagenlecleucel after second relapse (3/4) or refractory disease at first relapse (1/4). Three patients relapsed with CD19NEG/CD22POS BCP-ALL, one with CD19POS/CD22POS BCP-ALL. Following relapse, they received treatment with InO. After the first InO cycle, all achieved complete remission (CR), three without measurable residual disease. After two or three InO cycles, they underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient developed an isolated extramedullary relapse (IEM) in both anterior eye chambers six and nine months after allo-HSCT and received palliative radiotherapy. This patient was in CR at the last follow-up 25 months later. The other patients were also in CR at the last follow-up (mean 31.3 months).

Conclusion

InO can be used successfully and safely for the treatment of CD22POS BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信